Saskia Berger

Saskia Berger

Auto-generated profile, based on publicly available information

Saskia Berger

Center for Evidence-Based Healthcare, Faculty of Medicine, University Hospital Carl Gustav Carus at TUD Dresden University of Technology, Dresden, Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Infection
Verified
Journal Article
Open access
PDF file
FRFabian Reichel
Fabian Reichel
FTFalko Tesch
Falko Tesch
SBSaskia Berger
Saskia Berger
MSMartin Seifert
Martin Seifert
DKDirk Koschel
Dirk Koschel
MKMartin Kolditz
Martin Kolditz
Immunosuppression constitutes a significant risk for community-acquired pneumonia (CAP). Nevertheless, specific causes of immunosuppression and their relevance for incidence, etiology and prognosis of CAP are insufficiently investigated.We conducted a population-based cohort study within a statutory health insurance in Germany from 2015 to 2018. CAP was retrieved by ICD-10-GM codes. Episodes of immunosuppression were identified by coded conditions (hematologic neoplasms, stem cell or organ transplantation, neutropenia, HIV, primary immunosuppressive syndromes) or treatments (immunosuppressants, antineoplastic drugs, systemic steroids). Endpoints were defined as occurrence of CAP (primary), hospitalization, 30-day mortality and CAP associated with rare pathogens. Our analysis utilized the Andersen-Gill model adjusted for sex, age, level of long-term care, vaccination status, community type and comorbidities.942,008 individuals with 54,781 CAPs were included (hospitalization 55%, 30-day mortality 14.5%). 6% of individuals showed at least one episode of immunosuppression during the study period with systemic steroids (39.8%) and hematologic neoplasms (26.7%) being most common. Immunosuppression was recorded in 7.7% of CAPs. Besides classical risk factors such as age and level of long-term care, immunosuppressed patients were most prone to CAP (HR 2.4[2.3–2.5]) and consecutive death (HR 1.9[1.8–2.1]). Organ and stem cell transplantation (HR 3.2[2.6–4.0] and 2.8[2.1–3.7], respectively), HIV (HR 3.2[1.9–5.4]) and systemic steroids (> 20 mg prednisone daily dose equivalent (HR 2.7[2.4–3.1])) showed the highest risk for contracting CAP. CAP by rare pathogens was strongly associated with immunosuppression (HR 17.1[12.0–24.5]), especially HIV (HR 34.1[7.6–153]) and systemic steroids (HR 8.2[4.6–14.8]).Our study elucidates the relevance of particular immunosuppressive conditions including systemic steroids for occurrence and prognosis of CAP.

22 May 2020 in Allergy
Verified
Journal Article
Open access
PDF file
SFSaskia Fuhrmann
Saskia Fuhrmann
FTFalko Tesch
Falko Tesch
MRMarcel Romanos
Marcel Romanos
SASusanne Abraham
Susanne Abraham
JSJochen Schmitt
Jochen Schmitt
Click on the article title to read more.

25 January 2023 in JMIR Medical Informatics
Verified
Journal Article
Open access
Ines ReineckeInes Reinecke
Ines Reinecke
JSJoscha Siebel
Joscha Siebel
SFSaskia Fuhrmann
Saskia Fuhrmann
AFAndreas Fischer
Andreas Fischer
MSMartin Sedlmayr
Martin Sedlmayr
FBFranziska Bathelt
Franziska Bathelt
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Digitization offers a multitude of opportunities to gain insights for current diagnostics and therapy from retrospective data. In this context, real-world data and its accessibility are of increasing importance to support unbiased and reliable research on big data. However, routinely collected data are not readily usable for research due to the unstructured nature within healthcare systems and the lack of interoperability between these systems. This challenge is very evident in drug data. Objective: In this research, we present an approach that identifies and increases the structuredness of drug data while ensuring standardization according to ATC. Methods: Our approach is based on available drug prescriptions and a drug catalog and consists of four steps. First, we perform an initial analysis of the structuredness of local drug data to define a point of comparison for the effectiveness of the overall approach. Second, we apply three algorithms to unstructured data that translate text into ATC codes based on string comparisons in terms of ingredients and product names, and similarity comparisons based on Levenshtein distance. Third, we validated the results of the three algorithms with expert knowledge based on the 1000 most frequently used prescription texts. Fourth, we performed a final evaluation to determine the increased degree of structuredness. Results: Initially, 52.3% of the 1,768,153 drug prescriptions were classified as unstructured. With the application of the three algorithms, we were able to increase the degree of structuredness to 85.18% based on the 1000 most frequent medication prescriptions. In this regard, the combination of Algorithm 1, 2, and 3 resulted in a correctness level of 100% (with 57,264 ATC codes identified), Algorithm 1 and 3 of 99.6% (with 152,404 codes identified), and Algorithm 1 and 2 resulted in 95.9% (with 39,472 codes identified). Conclusions: As shown in the first analysis steps of our approach, the availability of a product catalog to select from during the documentation process is not sufficient to generate over structured data. Our four-step approach reduces the problems and reliably increases the structuredness automatically. Similarity matching shows promising results, especially for entries with no connection to a product catalog. However, further enhancement of the correctness of such a similarity matching algorithm needs to be investigated in future work. Clinical Trial: no trial registration The research was approved by the Ethics Committee at the Technical University of Dresden as a retrospective, observational, non-interventional, non-human subject study (SR-EK-521112021).

25 October 2023 in DMW - Deutsche Medizinische Wochenschrift
Verified
Journal Article
Open access
PDF file
SBSaskia Berger
Saskia Berger
HHHeike Hilgarth
Heike Hilgarth
AFAndreas Fischer
Andreas Fischer
YRYvonne Remane
Yvonne Remane
JSJochen Schmitt
Jochen Schmitt
HKHolger Knoth
Holger Knoth
Zusammenfassung: Einleitung Die Arzneimitteltherapie wird als Hochrisiko-Prozess bezeichnet und bedarf besonderer Aufmerksamkeit, insbesondere an den Sektorengrenzen. Pharmazeutische Dienstleistungen wie zum Beispiel eine Medikationsanalyse sind geeignete Maßnahmen zur Verbesserung der Arzneimitteltherapiesicherheit. Sie sind wirksam bei der Erkennung und Behebung von Arzneimittel-bezogenen Problemen. Risiko-Scoring-Tools sind in der Literatur als hilfreiches Instrument zur priorisierten Medikationsanalyse von Patient:innen mit Risiko für Arzneimittel-bezogene Probleme beschrieben.Methodik In einer Punkt-Prävalenzuntersuchung wurde unter Anwendung eines Medikationsrisiko-Tools der Anteil der Patient:innen mit einem erhöhten Risiko für Arzneimittel-bezogene Probleme bei Aufnahme ins Krankenhaus multizentrisch erfasst. Darüber hinaus wurde das Angebot pharmazeutischer Dienstleistungen durch die Krankenhausapotheken ermittelt.Ergebnisse Insgesamt haben sich 11 (58%; 11/19) Krankenhausapotheken in Sachsen an der Punkt-Prävalenzuntersuchung beteiligt. Es wurden 875 Patient:innen eingeschlossen. Bei 32% (279/875) der Patient:innen wurde ein erhöhtes Risiko für Arzneimittel-bezogene Probleme mittels Scoring-Tool (Meris-Score >12-Gruppe) ermittelt. Dabei betrug die Anzahl der Arzneistoffe in der Meris-Score >12-Gruppe 10,6 (Mittelwert; Standardabweichung 3,5; n=279), in der Meris-Score ≤12-Gruppe waren es nur fünf Arzneimittel pro Patient:in (Mittelwert 4,6; Standardabweichung 2,8; n=596). Das Alter der Patient:innen in der Meris-Score >12-Gruppe betrug im Mittel 75,9 ± 11 Jahre, während das Alter der Patient:innen in der Meris-Score ≤12-Gruppe im Mittel 60,6 ± 17,9 Jahre betrug.Diskussion Die Priorisierung mit Hilfe eines Scoring-Tools erschient bei den derzeit noch nicht regelhaft etablierten pharmazeutischen Dienstleistungen in sächsischen Krankenhäusern besonders wichtig, um Patient:innen mit einem erhöhten Risiko für Arzneimittel-bezogene Probleme frühzeitig zu identifizieren.

12 April 2024 in Drugs & Aging
Verified
Journal Article
Open access
PDF file
SBSaskia Berger
Saskia Berger
KMKristine F. Moseholm
Kristine F. Moseholm
EHEmilie R. Hegelund
Emilie R. Hegelund
FTFalko Tesch
Falko Tesch
MNMinh Chau S. Nguyen
Minh Chau S. Nguyen
KMKenneth J. Mukamal
Kenneth J. Mukamal
Background and Objective Preliminary evidence suggests a possible preventive effect of tumor necrosis factor-α inhibitors (TNFi) on incident dementia. The objective of the analysis was to investigate the association between TNFi and the risk of incident dementia in a population undergoing treatment for rheumatological disorders. Methods We followed patients aged ≥ 65 years with dementia and rheumatological conditions in two cohort studies, DANBIO (N = 21,538), a Danish clinical database, and AOK PLUS (N = 7112), a German health insurance database. We defined incident dementia using diagnostic codes and/or medication use and used Cox regression to compare the associations of TNFi with other rheumatological therapies on the risk of dementia. To ensure that the patients were receiving long-term medication, we included patients with rheumatic diseases and systemic therapies. Results We observed similar trends towards a lower risk of dementia associated with TNFi versus other anti-inflammatory agents in both cohorts (hazard ratios were 0.92 [95% confidence interval 0.76, 1.10] in DANBIO and 0.89 [95% confidence interval 0.63, 1.24] in AOK PLUS, respectively). Conclusions Tumor necrosis factor-α inhibitors may decrease the risk of incident dementia although the association did not reach statistical significance in this analysis. Further research, ideally with randomization, is needed to gauge the potential of repurposing TNFi for dementia prevention and/or treatment.

6 May 2026 in Infection
Verified
Journal Article
Open access
FRFabian Reichel
Fabian Reichel
FTFalko Tesch
Falko Tesch
SBSaskia Berger
Saskia Berger
MSMartin Seifert
Martin Seifert
DKDirk Koschel
Dirk Koschel
MKMartin Kolditz
Martin Kolditz
Although pneumocystis jirovecii pneumonia (PJP) in non-HIV patients is increasingly recognized, comprehensive data on immunosuppressive drivers remain limited. We conducted a population-based cohort study using a German health insurance’s claims data (2015–2023). PJP, comorbidities, immunocompromising conditions and therapies were identified by means of ICD-10-GM-, ATC- and OPS-coded records. 922,200 individuals were assessed for PJP occurrence, hospitalization and 30-day all-cause mortality. An Andersen-Gill model adjusted for key covariates. We identified 171 PJP episodes, with hospitalization in 88.3% and mortality in 24.5%. Frequent immunocompromising causes were hematologic cancers (42.6%), immunosuppressants (28.7%) and steroids (28.7%). Immunosuppression rather than typical CAP risk factors strongly predicted all outcomes (HR 49.9 [31.5–78.9]). Robust associations with PJP occurred for HIV (HR 67.5 [19.4–235]), systemic steroids (> 20 mg prednisone daily equivalent (HR 26.2 [13.2–52.1])) and hematologic cancers (HR 8.5 [4.5–16.3]). Mortality was driven by hematologic cancers (HR 13.9 [4.8–40.2]) and high-dose steroids (HR 8.6 [1.6–47.1]). Malignancy-related immunosuppression and steroids critically affect PJP risk and prognosis.